Stockholm - Delayed Quote SEK

BioInvent International AB (publ) (BINV.ST)

5.43 -0.28 (-4.90%)

At close: October 30 at 12:59:37 PM GMT+1

Invitation to Presentation of BioInvent's Interim Report January - September 2026

ACCESS Newswire 4d ago

BINV.ST
-4.90%
BioInvent's BI-1808 and KEYTRUDA(R) Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer

ACCESS Newswire 7d ago

BINV.ST
-4.90%
BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian Cancer at ESMO 2026

ACCESS Newswire 12d ago

BINV.ST
-4.90%
BioInvent Announces Publication of First-in-Human BI-1808 Data in Clinical Cancer Research

ACCESS Newswire 16d ago

BINV.ST
-4.90%
BioInvent International AB Announces that its CFO will Retire in 2027

ACCESS Newswire 19d ago

BINV.ST
-4.90%
BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research

ACCESS Newswire 2mo ago

BINV.ST
-4.90%
BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer

ACCESS Newswire 2mo ago

BINV.ST
-4.90%
BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models

ACCESS Newswire 3mo ago

BINV.ST
-4.90%
BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026

ACCESS Newswire 3mo ago

BINV.ST
-4.90%
BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

ACCESS Newswire 4mo ago

BINV.ST
-4.90%
Resolutions at BioInvent's Annual General Meeting 2026

ACCESS Newswire 5mo ago

BINV.ST
-4.90%
BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio

ACCESS Newswire 5mo ago

BINV.ST
-4.90%

U.S. markets closed

BioInvent International AB (publ) (BINV.ST)

Invitation to Presentation of BioInvent's Interim Report January - September 2026

BioInvent's BI-1808 and KEYTRUDA(R) Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer

BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian Cancer at ESMO 2026

BioInvent Announces Publication of First-in-Human BI-1808 Data in Clinical Cancer Research

BioInvent International AB Announces that its CFO will Retire in 2027

BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer

BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models

BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026

BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

Resolutions at BioInvent's Annual General Meeting 2026

BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio